• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form S-3/A filed by Ainos Inc.

    12/30/24 4:54:39 PM ET
    $AIMD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AIMD alert in real time by email
    S-3/A 1 forms-3a.htm

     

    As filed with the Securities and Exchange Commission on December 30, 2024

     

    Registration No. 333-284003

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    Amendment No.1

    to

    FORM S-3

    REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933

     

    AINOS, INC.

    (Exact name of registrant as specified in its charter)

     

    Texas   75-1974352
    (State or other jurisdiction of   (I.R.S. Employer
    incorporation or organization)   Identification Number)

     

    8880 Rio San Diego Drive, Ste. 800

    San Diego, CA 92108

    (858) 869-2986

    (Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

     

    CT Corporation System

    1999 Bryan St., Suite 900

    Dallas, TX 75201-3136

    (214) 979-1172

    (Name, address, including zip code, and telephone number, including area code, of agent for service)

     

    Copies to:

    Joseph M. Lucosky, Esq.

    Steven A. Lipstein, Esq.

    Lucosky Brookman LLP

    101 Wood Avenue South, 5th Floor

    Woodbridge, NJ 08830

    (732) 395-4400

     

    APPROXIMATE DATE OF COMMENCEMENT OF PROPOSED SALE TO THE PUBLIC: From time to time after the effective date of this registration statement.

     

    If the only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please check the following box. ☐

     

    If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plans, check the following box. ☒

     

    If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

     

    If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

     

    If this Form is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become effective on filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following box. ☐

     

    If this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D. filed to register additional securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following box. ☐

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one):

     

    Large accelerated filer ☐ Accelerated filer ☐
    Non-accelerated filer ☒ Smaller reporting company ☒
        Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

    The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933 or until the registration statement shall become effective on such date as the Commission, acting pursuant to said Section 8(a), may determine.

     

     

     

     
     

     

    EXPLANATORY NOTE

     

    We are filing this Amendment No. 1 (this “Amendment”) to its registration statement on Form S-3 (file No. 333-284003) as an exhibit-only filing. Accordingly, this Amendment consists only of the facing page, this explanatory note, Part II of the Registration Statement, the signature page to the registration statement and the filed exhibits. The remainder of the registration statement is unchanged and has therefore been omitted.

     

     
     

     

    PART II

     

    INFORMATION NOT REQUIRED IN PROSPECTUS

     

    Item 14. Other Expenses of Issuance and Distribution.

     

    The following is an estimate of the expenses (all of which are to be paid by the registrant) that we may incur in connection with the securities being registered hereby.

     

    SEC registration fee  $465 
    Legal fees and expenses*  $15,000 
    Accounting fees and expenses*  $1,500 
    Total*  $16,965 

     

    __________________

    *These fees are estimates.

     

    Item 15. Indemnification of Directors and Officers.

     

    Section 8.101 of the Texas Business Organizations Code allows a Texas corporation to indemnify a person who was, is, or is threatened to be made a defendant or respondent in a proceeding because the person is or was a director or officer if it is determined that the person (1) acted in good faith, (2) reasonably believed that his conduct in his official capacity as director was in the best interest of the corporation and in all other cases was at least not opposed to the corporation’s best interest, and (3) in the case of any criminal proceeding, had no reasonable cause to believe his conduct was unlawful. Indemnification under section 8.101 may be made for judgments, penalties, fines, settlements, and reasonable expenses actually incurred by the person in connection with the proceeding, subject to limitations provided therein. Section 8.051(A) requires indemnification of a defendant / respondent director or officer against reasonable expenses incurred by him in connection with a proceeding in which he has been wholly successful, on the merits or otherwise, in the defense of the proceeding. Our Bylaws provide for such limitation of liability.

     

    Item 16. Exhibits.

     

    (a) Exhibits

    A list of exhibits filed with this registration statement on Form S-3 is set forth on the Exhibit Index and is incorporated herein by reference.

     

    Item 17. Undertakings.

     

    The undersigned registrant hereby undertakes:

     

    (1) To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:

     

    (i) To include any prospectus required by Section 10(a)(3) of the Securities Act of 1933;

     

    (ii) To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20 percent change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective registration statement; and

     

    (iii)To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement.

     

    II-1
     

     

    (2) That for the purpose of determining any liability under the Securities Act of 1933 each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    (3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

     

    (4) That, for the purpose of determining liability under the Securities Act of 1933 to any purchaser, each prospectus filed pursuant to Rule 424(b) as part of a registration statement relating to an offering, other than registration statements relying on Rule 430B or other than prospectuses filed in reliance on Rule 430A, shall be deemed to be part of and included in the registration statement as of the date it is first used after effectiveness. Provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such first use, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such date of first use.

     

    (5) That, for the purpose of determining liability of the registrant under the Securities Act of 1933 to any purchaser in the initial distribution of the securities:

     

    The undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser:

     

    (i) Any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule 424;

     

    (ii)Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by the undersigned registrant;

     

    (iii)The portion of any other free writing prospectus relating to the offering containing material information about the undersigned registrant or its securities provided by or on behalf of the undersigned registrant; and

     

    (iv)Any other communication that is an offer in the offering made by the undersigned registrant to the purchaser.

     

    (6) Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers, and controlling persons of the Registrant pursuant to the provisions described in Item 14 above, or otherwise, the Registrant has been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer, or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer, or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

     

    (7) The undersigned Registrant hereby undertakes:

     

    (i) That for purposes of determining any liability under the Securities Act, the information omitted from the form of prospectus filed as part of this registration statement in reliance upon Rule 430A and contained in a form of prospectus filed by the Registrant pursuant to Rule 424(b)(1) or (4), or 497(h) under the Securities Act shall be deemed to be part of this registration statement as of the time it was declared effective.

     

    (ii)That for the purpose of determining any liability under the Securities Act, each post-effective amendment that contains a form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and this offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    II-2
     

     

    EXHIBIT INDEX

     

    Exhibit No.   Exhibit Description
         
    5.1*   Opinion of Lucosky Brookman LLP
    10.1  

    Ainos, Inc. 2021 Stock Incentive Plan (incorporated by reference to Exhibit 4.1 to Ainos Inc.’s registration statement on Form S-8 filed with the SEC on July 7, 2022).

    10.2  

    Ainos, Inc. 2023 Stock Incentive Plan (incorporated by reference to Exhibit 4.1 to Ainos Inc.’s registration statement on Form S-8 filed with the SEC on June 14, 2023).

    23.1**   Consent of KCCW Accountancy Corp.
    23.2*   Consent of Lucosky Brookman LLP (reference is made to Exhibit 5.1)
    24.1**   Power of Attorney (included on the signature page of this Registration Statement)
    107 **   Filing Fee Table

     

     

    *Filed herewith.

    **Previously filed.

     

    II-3
     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-3 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Taipei, Taiwan (R.O.C.), on December 30, 2024.

     

    AINOS, INC.  
       
    By: /s/ Chun-Hsien Tsai  
      Chun-Hsien Tsai, Chairman of the Board,  
      President, and Chief Executive Officer  

     

    POWER OF ATTORNEY

     

    Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed below by the following persons in the capacities and on the dates indicated.

     

    Signature   Title   Date
             
    /s/ Chun-Hsien Tsai   Chairman of the Board, President and Chief Executive Officer   December 30, 2024
    Chun-Hsien Tsai        
             
    *   Chief Financial Officer   December 30, 2024
    Christopher Hsin-Liang Lee        
             
    *   Director   December 30, 2024
    Wen-Han Chang        
             
    *   Director   December 30, 2024
    Yao-Chung Chiang        
             
    *   Director   December 30, 2024
    Pao-Sheng Wei        
             
    *   Director   December 30, 2024
    Ting-Chuan Lee        
             
    *   Director   December 30, 2024
    Chun-Jung Tsai        
             
    *   Director   December 30, 2024
    Chung-Yi Tsai        

     

    * By: /s/ Chun-Hsien Tsai  
      Chun-Hsien Tsai  
      Attorney-in-fact  

     

    II-4

     

    Get the next $AIMD alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AIMD

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $AIMD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Water Tower Research Spotlights Ainos' AI Nose Programs and Strategic Milestones for 2025

    Report highlights greater visibility in AI Nose developments, including robotics, smart manufacturing, elderly care monitoring, and women's health testing SAN DIEGO, CA / ACCESS Newswire / January 21, 2025 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), a pioneer of digiting scent and low-dose interferon therapeutics, today announced that Water Tower Research ("WTR") has published a report projecting increased visibility for the Company's transformative AI Nose programs. The report emphasizes anticipated progress for AI Nose across multiple sectors, including robotics, smart manufacturing, elderly care, and women's health.Key Highlights from the Report:AI Nose Technolog

    1/21/25 10:00:00 AM ET
    $AIMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ainos Granted 180-Day Extension by Nasdaq to Regain Compliance With Minimum Bid Price Rule

    SAN DIEGO, CA / ACCESS Newswire / January 17, 2025 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos", or the "Company"), today announced that it had received written notification (the "Written Notification") from the Listing Qualifications Department of the Nasdaq Stock Market LLC ("Nasdaq") that the Company is eligible for a 180-day extension to regain compliance with the $1.00 minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) (the "Rule").As previously reported, on July 15, 2024, the Company received a deficiency letter from the Nasdaq notifying the Company that, for the last 30 consecutive business days, the closing bid price for the Company's common stock has been below

    1/17/25 9:00:00 AM ET
    $AIMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ainos Unveils AI Nose for Robotics: Invites Global Robotics Companies to Join Forces in Shaping the Future of Smell-Enabled Robots

    Ainos invites robotics and humanoid companies to join Ainos Alliance and digitize smell SAN DIEGO, CA / ACCESSWIRE / January 13, 2025 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW), a pioneer of digitizing scent, proudly announces its revolutionary AI Nose for robotics application and invites robotics companies worldwide to join Ainos Alliance. This technology aims to equip robots with the ability to "smell," filling a long-standing gap in sensory capabilities. Powered by advanced artificial intelligence (AI) and micro-electromechanical systems (MEMS) gas sensors, AI Nose redefines how robots interact with the world, enabling transformative applications across industrial, healthcare, and everyday

    1/13/25 10:00:00 AM ET
    $AIMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AIMD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Ase Test, Inc. bought 29,476 shares (SEC Form 4)

    4 - Ainos, Inc. (0001014763) (Issuer)

    6/25/25 6:03:05 AM ET
    $AIMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AIMD
    SEC Filings

    View All

    Ainos Inc. filed SEC Form 8-K: Other Events

    8-K - Ainos, Inc. (0001014763) (Filer)

    1/6/26 8:30:46 AM ET
    $AIMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ainos Inc. filed SEC Form 8-K: Regulation FD Disclosure

    8-K - Ainos, Inc. (0001014763) (Filer)

    1/5/26 8:30:31 AM ET
    $AIMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ainos Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities

    8-K - Ainos, Inc. (0001014763) (Filer)

    12/31/25 4:10:38 PM ET
    $AIMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AIMD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Taiwan Carbon Nano Technology Corp sold $99,806 worth of shares (46,000 units at $2.17), decreasing direct ownership by 4% to 989,925 units (SEC Form 4)

    4 - Ainos, Inc. (0001014763) (Issuer)

    1/29/26 7:32:38 PM ET
    $AIMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Taiwan Carbon Nano Technology Corp sold $2,336 worth of shares (1,281 units at $1.82), decreasing direct ownership by 0.12% to 1,035,925 units (SEC Form 4)

    4 - Ainos, Inc. (0001014763) (Issuer)

    1/12/26 4:10:18 PM ET
    $AIMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CEO, PRESIDENT, CHAIRMAN Tsai Chun-Hsien was granted 80,000 shares, increasing direct ownership by 24% to 410,372 units (SEC Form 4)

    4 - Ainos, Inc. (0001014763) (Issuer)

    11/26/25 4:10:14 PM ET
    $AIMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AIMD
    Financials

    Live finance-specific insights

    View All

    Ainos Reports Third Quarter 2024 Financial Results

    Secured multi-regional patent assets, strengthening Ainos' AI Nose technology.Expanded VELDONA® patent portfolio with a new invention patent for treatments and preventions for coronavirus infections.Progressed clinical trials for VELDONA®, including new studies on Sjögren's syndrome and HIV-related oral warts. SAN DIEGO, CA / ACCESSWIRE / November 6, 2024 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos", or the "Company"), an innovative healthcare company focused on advanced AI-driven point-of-care testing ("POCT") and low-dose interferon therapeutics, today announced its financial results for the third quarter ended September 30, 2024.Chun-Hsien (Eddy) Tsai, Chairman of the Board, Preside

    11/6/24 4:30:00 PM ET
    $AIMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ainos Reports Second Quarter 2024 Financial Results

    Enrolling first subject for FCGS clinical study marks a solid start in shifting animal health emphasis to drug developmentsRobust financial runway for over 12 months following the prepayment of a senior secured convertible noteSAN DIEGO, CA / ACCESSWIRE / August 5, 2024 / Ainos, Inc. (NASDAQ:AIMD, AIMDW))) ("Ainos", or the "Company"), a diversified healthcare company focused on novel AI-powered point-of-care testing ("POCT") and low-dose interferon therapeutics ("VELDONA®"), today announced its financial results for the second quarter ended June 30, 2024.Chun-Hsien (Eddy) Tsai, Chairman of the Board, President, and Chief Executive Officer of Ainos, commented, "We've made meaningful progress

    8/5/24 4:15:00 PM ET
    $AIMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ainos Reports First Quarter 2024 Financial Results

    Strategic focus on VELDONA and AI-powered point-of-care testing continues during 2024US$9M growth capital secured in May strengthens financial position for executing growth strategy SAN DIEGO, CA / ACCESSWIRE / May 13, 2024 / Ainos, Inc. (NASDAQ:AIMD, AIMDW))) ("Ainos", or the "Company"), a diversified healthcare company focused on the development of novel point-of-care testing ("POCT"), low-dose interferon therapeutics, and synthetic RNA-driven preventative medicine, today announced its financial results for the first quarter ended March 31, 2024.Chun-Hsien (Eddy) Tsai, Chairman of the Board, President, and Chief Executive Officer of Ainos, commented, "In the first quarter, we successfully

    5/13/24 4:10:00 PM ET
    $AIMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AIMD
    Leadership Updates

    Live Leadership Updates

    View All

    Ainos Unveils AI Nose for Robotics: Invites Global Robotics Companies to Join Forces in Shaping the Future of Smell-Enabled Robots

    Ainos invites robotics and humanoid companies to join Ainos Alliance and digitize smell SAN DIEGO, CA / ACCESSWIRE / January 13, 2025 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW), a pioneer of digitizing scent, proudly announces its revolutionary AI Nose for robotics application and invites robotics companies worldwide to join Ainos Alliance. This technology aims to equip robots with the ability to "smell," filling a long-standing gap in sensory capabilities. Powered by advanced artificial intelligence (AI) and micro-electromechanical systems (MEMS) gas sensors, AI Nose redefines how robots interact with the world, enabling transformative applications across industrial, healthcare, and everyday

    1/13/25 10:00:00 AM ET
    $AIMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AIMD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Ainos Inc.

    SC 13D/A - Ainos, Inc. (0001014763) (Subject)

    11/27/24 6:08:44 AM ET
    $AIMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D filed by Ainos Inc.

    SC 13D - Ainos, Inc. (0001014763) (Subject)

    8/21/24 8:22:28 PM ET
    $AIMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Ainos Inc.

    SC 13D/A - Ainos, Inc. (0001014763) (Subject)

    8/20/24 4:05:21 PM ET
    $AIMD
    Biotechnology: Pharmaceutical Preparations
    Health Care